| Overview |
| bs-6568R-Cy3 |
| PCANAP2 Polyclonal Antibody, Cy3 Conjugated |
| WB |
| Rat |
| Human, Mouse, Dog, Cow, Sheep, Pig, Arabidopsis Thaliana |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PCANAP2 |
| 351-450/553 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 85414 |
| Cell membrane |
| IPCA 2; IPCA 8; IPCA6; PCANAP2; PCANAP6; PCANAP8; Prostate cancer associated gene 2; Prostate cancer associated gene 6; Prostate cancer associated gene 8; Prostate cancer associated protein 2; Prostate cancer associated protein 6; Prostate cancer associated protein 8; Prostate cancer-associated protein 6; Prostein; PRST; S45A3_HUMAN; Slc45a3; Solute carrier family 45 member 3. |
| PSA, prostate specific antigen, is the classic indicator for transformed pro-state tissue; however, in addition to being upregulated in prostate cancer, PSA is also upregulated in non-malignant conditions, such as benign prostatic hyperplasia. Prostein, also designated Prostate cancer-associated protein 6, is a prostate-specific, 553 amino acid transmembrane protein that is upregulated by androgens. It is considered a marker for prostate cells since it is expressed in all prostatic glandular cells as well as in normal and cancerous prostate tissues. Since it is able to elicit a tumor-directed cytotoxic T cell response, Prostein may be used as a target for the development of PSA- and T cell-based therapeutic strategies for prostate cancer. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz